P369 Efficacy of Infliximab after Failure of Subcutaneous Anti-Tnf Agents in Patients with Ulcerative Colitis: A Multicentre Study

s of the 13th Congress of ECCO – European Crohn’s and Colitis Organisation S291 Methods: Retrospective review of electronic health records (TrakCare) was performed on all patients who have received infliximab (IFX), adalimumab (ADA), vedolizumab (VEDO), or ustekinumab (UST) in Edinburgh from January 1999 to October 2017. We collected data for demographics, phenotyping details, and duration of treatment. Kaplan–Meier survival curves and log-rank analyses were used to compare time to either discontinuation or resectional surgery. Results: A total of 841 patients were identified who have had biologic therapy for IBD. Median interval from diagnosis to biologic was 4.9 years (IQR 1.3–11.0). The multiple combinations of biologics used is displayed in Figure 1. A total of 601 CD patients (79.7% of total) were treated with biologics; 486 of 601 received IFX (73.1%), 169 of 601 ADA (25.4%), and 10 of 601 VEDO (1.6%) as first-line therapy. Second-line therapy was required in 238 patients and consisted of ADA 189 (79.4%), IFX 25 (10.9%), VEDO 18 (7.6%), and UST 6 (2.5%). Third-line therapy was required in 57 patients, VEDO 41 (74.5%) and UST 14 (25.5%). Three (0.5%) patients received fourth line therapy with UST. In the CD, cohort persistence of treatment on ADA was longer than IFX when used as first-line treatment; median 2373 vs. 1430 days (p = 0.0189). Venn diagram of patient biologic journey Conclusions: Multiple sequential biologic use is becoming increasingly common and this will accelerate with the increasing use of anti-integrin and anti-IL12/IL23 therapies. Mapping the sequence of biologic use and linking this to outcomes is a priority for IBD research.